The Oncology Institute Chief Medical Officer to Speak on Value-Based Specialty Care at APG Spring Conference

GlobeNewswire
05/26

CERRITOS, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Yale D. Podnos, MD, MPH, FACS, Chief Medical Officer, will participate in a panel discussion at the APG Spring Conference on May 28, 2026, in San Diego. The session, "Engaging More Specialists in Value-Based Care," will bring together healthcare leaders to discuss the growing role of specialists in advancing value-based care.

"Specialists play a critical role in delivering high-quality, coordinated care while helping improve outcomes and reduce the total cost of care," said Dr. Podnos. "As oncology continues to evolve, value-based models create opportunities to enhance the patient experience, maximize quality of life and survival outcomes, and improve care quality and patient safety."

Dr. Podnos will share insights on oncology's role in improving outcomes, reducing costs, and advancing value-based care delivery.

About The Oncology Institute (www.theoncologyinstitute.com):
Founded in 2007, The Oncology Institute (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.9 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 180 employed and affiliate clinicians and over 100 clinics and affiliate locations of care across five states and growing, TOI is changing oncology for the better.

Media
The Oncology Institute, Inc.
marketing@theoncologyinstitute.com

Investors
ICR Healthcare
TOI@icrhealthcare.com


免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10